insulin sensitivity Inhibitors
1 drugsAbout insulin sensitivity
Insulin sensitivity reflects how efficiently cells respond to insulin, influencing glucose uptake and blood sugar regulation. Reduced insulin sensitivity, or insulin resistance, is a hallmark of metabolic disorders like type 2 diabetes.
While direct genetic evidence linking insulin sensitivity to specific diseases is unavailable, its crucial role in glucose metabolism makes it a key therapeutic target. Improving insulin sensitivity can help manage diabetes and potentially prevent its progression.
Currently, one FDA-approved drug, XIGDUO XR (small molecule), targets insulin sensitivity for metabolic indications. AstraZeneca is the sole company with an approved drug in this space.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 82% attractiveness score.
- White space opportunity in Albuminuria with only 4 trials.
Top insulin sensitivity Drugs
AstraZeneca is the only company with an approved drug targeting insulin sensitivity.
Low competition suggests high entry barriers or untapped market potential for new entrants.
insulin sensitivity Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets insulin sensitivity, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel therapeutic approaches.
insulin sensitivity Clinical Trials 403 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 65 | 48 | 4 | 13 | 92% |
| Phase 2 | 88 | 41 | 12 | 34 | 77% |
| Phase 3 | 113 | 67 | 3 | 41 | 96% |
| Phase 4 | 137 | 86 | 13 | 35 | 87% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved insulin sensitivity drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting insulin sensitivity. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
insulin sensitivity Drug Approval Timeline (2014 - 2014)
The first and only drug, XIGDUO XR, was approved in 2014.
The lack of recent approvals indicates potential saturation or challenges in developing new therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 9 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 352 clinical trials targeting insulin sensitivity.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities